RHOA and cancer: A specific requirement for PKN2 in cell migration has previously been shown in cancer cells and in vivo (Lachmann et al., 2011, Quétier et al., 2016), suggesting that RhoA effector kinases synergize to control F-actin organization and contractility in rear retraction.